Abstract:This study introduces RC‐K‐FX, a peptide nanomaterial that self‐assembles into spherical structures within cells, addressing the impact of the tumor's intrinsic repair mechanisms on therapeutic efficacy. RC‐K‐FX not only damages mitochondria but also stably inhibits MUC1‐C dimerization, blocking the repair of stress‐induced mitochondrial damage in tumor cells. RC‐K‐FX can treat tumors while simultaneously inhibiting tumor metastasis. Mitochondria‐targeted cancer therapy is an effective method for controlling tumor growth. However, the presence of repair mechanisms in tumor cells in response to mitochondrial damage poses significant challenges for treatment. By taking advantage of intracellular self‐assembly technology, a peptide nanomaterial, RC‐K‐FX, that enters tumor cells in a monomeric form is designed. After binding to MUC1‐C inside the cell membrane, RC‐K‐FX assembles into a spherical structure that stably encapsulates MUC1‐C, inhibiting its dimerization and blocking the repair of stress‐induced mitochondrial damage in tumor cells. Moreover, the self‐assembled mitochondrial toxic peptide effectively destroys the mitochondria, and the loss of mitochondrial repair significantly increases tumor cytotoxicity by disrupting the redox balance, enhancing reactive oxygen species (ROS), inhibiting the nuclear factor (NF)‐κB pathway, and suppressing the epithelial‐mesenchymal transition (EMT) process. After intravenous administration, RC‐G‐FX accumulated at the tumor site, exhibiting improved anti‐tumor effects and extending the overall survival of tumor‐bearing mice. Therefore, the integration of the in situ self‐assembly of peptide drugs and damage to mitochondrial repair mechanisms provides effective therapeutic options for malignancy.

Rational design of self-assembled mitochondria- targeting lytic peptide conjugates with enhanced tumor selectivity.

Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

Self-Assembled Peptide-Lanthanide Nanoclusters for Safe Tumor Therapy: Overcoming and Utilizing Biological Barriers to Peptide Drug Delivery.

Self‐Assembly of Therapeutic Peptide into Stimuli‐Responsive Clustered Nanohybrids for Cancer‐Targeted Therapy

Redox-responsive self-assembled peptide hydrogel for mitochondrial-targeted anticancer drug delivery

Lysosome‐Targeted and Fluorescence‐Turned “On” Cytotoxicity Induced by Alkaline Phosphatase‐Triggered Self‐Assembly

A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death

Tumor‐Specific Protein Induced in Situ Self‐Assembly of Peptide Drugs for Synergistic Mitochondria Disruption

A Self-Delivery Membrane System for Enhanced Anti-Tumor Therapy

Rationally Designed Enzyme‐Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer Treatment

Assemblies of Peptide-Cytotoxin Conjugates for Tumor-Homing Chemotherapy

Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency

Mitochondria-targeted cancer therapy based on functional peptides

Enhanced Tumor-Targeted Delivery of Arginine-Rich Peptides via a Positive Feedback Loop Orchestrated by Piezo1/integrin β1 Signaling Axis

Combinatorial Targeting Polymeric Micelles for Anti-Tumor Drug Delivery.

A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity

Mitochondrion-specific Dendritic Lipopeptide Liposomes for Targeted Sub-Cellular Delivery

Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles